"""
Question: 1101 

Evidence: A retrospective study was conducted with patients with AHI from 2012 to 2017 in West China Hospital. Results: A total of 47 patients with AHI were found using a fourth‐generation kit.

Rationale: The paper describes a retrospective analysis of patients screened and identified at a specific hospital over 2012–2017, reporting counts, characteristics, and analyses that were not previously published elsewhere.

Answer: Yes
"""

"""
Question: 1102 

Evidence: We performed genotyping and drug resistance detection of AHI strains, among which 34 were sequenced successfully. Figure 3 Phylogenetic tree of HIV pol sequences from 34 patients with AHI.

Rationale: The methods and results explicitly state that sequences were generated and analyzed, and a phylogenetic tree of pol sequences from 34 patients is presented.

Answer: Yes
"""

"""
Question: 1103 

Evidence: HIV-1 RNA was extracted from blood using QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). PCRs were sent to TsingKe Biological Technology in Chengdu for direct DNA sequencing.

Rationale: The study sequenced patient-derived viral RNA from blood and did not describe any laboratory in vitro passage of virus; methods focus on direct sequencing of clinical specimens.

Answer: No
"""

"""
Question: 1104 

Evidence: Mutation sites and genotypes of drug resistance were determined using the Stanford University HIV Drug Resistance Database. We performed genotyping and drug resistance detection of AHI strains.

Rationale: The study reports genotypic resistance analysis inferred from sequences; it does not describe any phenotypic in vitro antiretroviral susceptibility testing (e.g., IC50 assays).

Answer: No
"""

"""
Question: 2101 

Evidence: We performed genotyping and drug resistance detection of AHI strains, among which 34 were sequenced successfully. Figure 3 Phylogenetic tree of HIV pol sequences from 34 patients with AHI.

Rationale: Although sequences were generated and analyzed, the text does not provide GenBank accession numbers for these newly sequenced isolates.

Answer: No
"""

"""
Question: 2102 

Evidence: We performed genotyping and drug resistance detection of AHI strains, among which 34 were sequenced successfully. Figure 3 Phylogenetic tree of HIV pol sequences from 34 patients with AHI.

Rationale: The paper does not list GenBank accession numbers for any of the patient-derived sequences (which are non-laboratory isolates).

Answer: No
"""

"""
Question: 2103 

Evidence: CRF07_BC was homologous to the Xinjiang representative strain 07_BC.CN.98.98CN009.AF286230 discovered in 1998. CRF01_AE was close to 01_AE.TH.90.CM240.U54771 of Thailand and 01_AE.CN.05.05GX001.GU564221 of Guangxi, China. CRF08_BC shared homology with 08_BC.CN.97.97 CNGX_6F.AY008715 in Guangxi. CRF55_01B … was close to Guangdong representative strain CN. 2011. GDDG318. JX574662 (CRF55_01B).

Rationale: The paper mentions GenBank accession numbers for reference strains used in phylogenetic comparisons, even though it does not provide accession numbers for its own sequences.

Answer: AF286230; U54771; GU564221; AY008715; JX574662
"""

"""
Question: 2202 

Evidence: Primary drug resistance mutations occurred in six cases, two in PR region and four in RT region. Mutations in PR region were M46I and Q58E. Four drug resistance mutations in RT region were all nonnucleoside reverse transcriptase inhibitors with one E138A, one V179D, and two V179Es.

Rationale: Mutations are reported in aggregate (counts by mutation), not as per-isolate mutation lists for each individual sequence.

Answer: No
"""

"""
Question: 2301 

Evidence: HIV-1 RNA results were collected from the hospital laboratory information system. HIV-1 RNA was extracted from blood using QIAamp Viral RNA Mini Kit.

Rationale: The study consistently refers to HIV-1 in RNA extraction and testing.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: In these AHI strains, four HIV clades were identified: CRF07_BC (64.71%), CRF01_AE (26.47%), CRF55_01B (5.88%), and CRF08_BC (2.94%). The main genetic forms of AHI were CRF07_BC and CRF01_AE, and a rare subtype CRF55_01B in Sichuan province was found.

Rationale: The paper lists the subtypes/CRFs identified among the sequenced strains.

Answer: CRF07_BC; CRF01_AE; CRF55_01B; CRF08_BC
"""

"""
Question: 2303 

Evidence: …a product of 1.3 kb including the whole PR gene and the first 300 amino acids of RT gene located in pol sequence. Phylogenetic tree of HIV pol sequences from 34 patients with AHI.

Rationale: The sequenced region includes the full protease gene and the N-terminal portion of reverse transcriptase within pol.

Answer: Protease (PR) and the first 300 amino acids of reverse transcriptase (RT) in pol
"""

"""
Question: 2304 

Evidence: Phylogenetic tree of HIV pol sequences from 34 patients with AHI. …including the whole PR gene and the first 300 amino acids of RT gene located in pol sequence.

Rationale: Both the figure and methods confirm that pol sequences were obtained and analyzed.

Answer: Yes
"""

"""
Question: 2401 

Evidence: …patients with AHI from 2012 to 2017 in West China Hospital. …one of the largest general teaching hospitals in China… in Sichuan province… CRF55_01B was first reported in Chengdu, Sichuan province…

Rationale: The sequences were from patients at West China Hospital in Chengdu, Sichuan province, China (western China).

Answer: Chengdu, Sichuan province, China (western China)
"""

"""
Question: 2402 

Evidence: The study enrolled patients who received HIV screenings in West China Hospital between 2012 and 2017. A total of 47 AHI were found between 2012 and 2017.

Rationale: Sequenced samples derive from the AHI cases identified during 2012–2017.

Answer: 2012–2017
"""

"""
Question: 2502 

Evidence: PCRs were sent to TsingKe Biological Technology in Chengdu for direct DNA sequencing. ChromasPro 1.33 software was used to edit and stitch sequences.

Rationale: “Direct DNA sequencing” of PCR amplicons is consistent with Sanger sequencing rather than NGS.

Answer: Yes
"""

"""
Question: 2503 

Evidence: PCRs were sent … for direct DNA sequencing. Nested PCR was performed … and PCRs were sent … for direct DNA sequencing.

Rationale: The methods describe nested PCR followed by direct (Sanger) sequencing; no next-generation sequencing is mentioned.

Answer: No
"""

"""
Question: 2504 

Evidence: Nested PCR … PCRs were sent … for direct DNA sequencing. Complementary DNA was synthesized … and then used to amplify a product … located in pol sequence.

Rationale: They directly sequenced PCR products without describing cloning of amplicons into vectors.

Answer: No
"""

"""
Question: 2505 

Evidence: PCRs were sent … for direct DNA sequencing. Nested PCR was performed … and then directly sequenced.

Rationale: The study does not describe single-genome sequencing; instead, bulk PCR products were directly sequenced.

Answer: No
"""

"""
Question: 2506 

Evidence: PCRs were sent … for direct DNA sequencing. Nested PCR was performed … and then directly sequenced.

Rationale: No molecular cloning of viral sequences (e.g., into plasmids) is described.

Answer: No
"""

"""
Question: 2601 

Evidence: HIV-1 RNA was extracted from blood using QIAamp Viral RNA Mini Kit. Complementary DNA was synthesized … and then used to amplify … pol sequence.

Rationale: Sequencing was performed on cDNA derived from plasma/blood viral RNA, indicating plasma HIV sequencing results.

Answer: Yes
"""

"""
Question: 2602 

Evidence: HIV-1 RNA was extracted from blood using QIAamp Viral RNA Mini Kit. Complementary DNA was synthesized … and then used to amplify … pol sequence.

Rationale: The methods specify RNA extraction and cDNA sequencing; there is no mention of PBMC DNA or proviral DNA sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: HIV-1 RNA was extracted from blood … and then used to amplify … pol sequence. We performed genotyping and drug resistance detection of AHI strains, among which 34 were sequenced successfully.

Rationale: All successfully sequenced samples (34) were derived from blood viral RNA.

Answer: 34
"""

"""
Question: 2604 

Evidence: HIV-1 RNA was extracted from blood … for direct DNA sequencing. There is no description of PBMC or proviral DNA extraction for sequencing.

Rationale: Only plasma/blood RNA-derived sequences were reported; PBMC sequencing was not performed.

Answer: 0
"""

"""
Question: 2605 

Evidence: AHI is a vital stage in the process of HIV infection. During this period of time, viral loads are at the peak of the whole course of HIV infection. HIV-1 RNA was extracted from blood using QIAamp Viral RNA Mini Kit.

Rationale: Sequencing was performed on RNA from patients in acute infection with high viral loads, indicating active replication.

Answer: Yes
"""

"""
Question: 2606 

Evidence: HIV-1 RNA was extracted from blood … Complementary DNA was synthesized … and then used to amplify … pol sequence.

Rationale: Sequencing targeted circulating viral RNA, not proviral DNA; no reservoir sequencing is described.

Answer: No
"""

"""
Question: 2701 

Evidence: Median age of patients with AHI was 26 and 91.49% of them were males. In our study, young males were the dominant group among 47 patients with acute HIV.

Rationale: The cohort comprises predominantly adults with a median age of 26; no infants or children are mentioned.

Answer: No
"""

"""
Question: 2702 

Evidence: A retrospective study was conducted with patients with AHI from 2012 to 2017 in West China Hospital. As a retrospective analysis of routinely collected programmatic data, the study was deemed exempt from review by the Ethics Committee.

Rationale: The study was observational and retrospective, not a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: A retrospective study was conducted with patients with AHI from 2012 to 2017 in West China Hospital. As a retrospective analysis of routinely collected programmatic data, the study was deemed exempt from review…

Rationale: Since the study was not a clinical trial, it is not possible that all individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: We performed genotyping and drug resistance detection of AHI strains, among which 34 were sequenced successfully. Figure 3 … HIV pol sequences from 34 patients with AHI.

Rationale: The number of individuals with sequenced samples is explicitly reported as 34.

Answer: 34
"""

"""
Question: 3102 

Evidence: A total of 47 patients with AHI were found … We performed genotyping … among which 34 were sequenced successfully.

Rationale: Not all 47 AHI individuals had successful sequencing; only 34 did.

Answer: No
"""

"""
Question: 4101 

Evidence: We performed genotyping and drug resistance detection of AHI strains… Primary drug resistance mutations occurred in six cases. AHI refers to the period from viral acquisition to emergence of specific antibodies.

Rationale: “Primary” (transmitted) resistance is evaluated in untreated individuals, and the cohort consists of acute infections prior to ART initiation.

Answer: Yes
"""

"""
Question: 4102 

Evidence: Primary drug resistance mutations occurred in six cases… The mutation rate of drug resistance in AHI was relatively high… (discussion focuses on transmitted resistance). There is no description of prior ARV exposure.

Rationale: The study centers on acute, untreated infections; no sequences from previously treated individuals are described.

Answer: No
"""

"""
Question: 4103 

Evidence: We performed genotyping … AHI strains… Primary drug resistance mutations occurred in six cases. There is no description of prior ARV exposure or ART-experienced individuals.

Rationale: Only ART-naive (acute) cases are described; no ART-experienced sequences are reported.

Answer: No
"""

"""
Question: 4104 

Evidence: We performed genotyping and drug resistance detection of AHI strains, among which 34 were sequenced successfully. Primary drug resistance mutations occurred in six cases.

Rationale: All sequenced AHI strains are from pre-treatment (acute) individuals; hence the number of samples from ART-naive individuals equals the number sequenced.

Answer: 34
"""

"""
Question: 4105 

Evidence: A retrospective study was conducted… We performed genotyping and drug resistance detection… (no ART regimen histories are described). The study focuses on screening, staging, and baseline genotyping.

Rationale: The text does not provide detailed ART history information for individuals; treatment histories are not reported.

Answer: No
"""

"""
Question: 4201 

Evidence: Primary drug resistance mutations occurred in six cases… The drug resistance mutation rate was relatively high (17.65%) and five different mutations were identified.

Rationale: The paper reports the proportion of acute infections with transmitted (primary) resistance mutations.

Answer: Yes
"""

"""
Question: 4202 

Evidence: Primary drug resistance mutations occurred in six cases… The drug resistance mutation rate was relatively high (17.65%)…

Rationale: Primary/transmitted resistance in untreated individuals constitutes pretreatment resistance prevalence.

Answer: Yes
"""

"""
Question: 4301 

Evidence: The study was a retrospective screening and genotyping analysis of acute infections, with focus on clinical, virological, and molecular epidemiological characteristics. No antiretroviral treatment regimens received by individuals are described.

Rationale: The paper does not report any ART regimens or drug classes received by participants.

Answer: NA
"""

"""
Question: 4302 

Evidence: The study focuses on baseline screening and genotyping in AHI and does not describe treatment regimens. No mentions of integrase inhibitors or integrase gene sequencing are made.

Rationale: There is no information on individuals receiving integrase inhibitors.

Answer: NA
"""

"""
Question: 4303 

Evidence: Mutations in PR region were M46I and Q58E. The paper does not describe treatment regimens received by individuals.

Rationale: Although protease mutations are reported, ART use (including PI receipt) by individuals is not described.

Answer: NA
"""

"""
Question: 4304 

Evidence: The article reports on screening and baseline genotyping in AHI without listing ART regimens. No treatment regimen data are provided.

Rationale: Without any ART regimen data, it cannot be determined whether all individuals received the same ART.

Answer: NA
"""

"""
Question: 4305 

Evidence: The study does not report ART histories or regimens for participants. Only PR and RT regions were sequenced; no integrase sequencing or INSTI exposure is described.

Rationale: INSTI exposure status is not reported.

Answer: NA
"""

"""
Question: 4403 

Evidence: The paper contains no information on ART regimens administered to individuals. It focuses on screening, staging, and genotyping.

Rationale: Without ART data, the number receiving more than one regimen cannot be determined.

Answer: NA
"""

"""
Question: 4404 

Evidence: The paper contains no information on ART regimens administered to individuals. It focuses on screening, staging, and genotyping.

Rationale: Without ART data, the number receiving more than two regimens cannot be determined.

Answer: NA
"""

"""
Question: 4405 

Evidence: No antiretroviral treatment data are provided for the cohort. The study centers on baseline characteristics and genotyping.

Rationale: The uniformity in number of ART regimens cannot be assessed.

Answer: NA
"""

"""
Question: 4406 

Evidence: No antiretroviral treatment data are provided for the cohort. The study centers on baseline characteristics and genotyping.

Rationale: It is not reported whether all individuals received a single regimen.

Answer: NA
"""

"""
Question: 4501 

Evidence: The study does not report any ART drugs received by individuals. It focuses on detection and baseline genotyping in acute infection.

Rationale: There is no information about dolutegravir use.

Answer: NA
"""

"""
Question: 4502 

Evidence: The study does not report any ART drugs received by individuals. It focuses on detection and baseline genotyping in acute infection.

Rationale: There is no information about darunavir use.

Answer: NA
"""

"""
Question: 5101 

Evidence: Primary drug resistance mutations occurred in six cases, two in PR region and four in RT region. The drug resistance mutation rate was relatively high (17.65%)…

Rationale: The text explicitly states six cases with primary resistance among the sequenced AHI strains.

Answer: 6
"""

"""
Question: 5102 

Evidence: Mutation sites and genotypes of drug resistance were determined using the Stanford University HIV Drug Resistance Database. Sequencing targeted PR and RT (pol) but did not include the integrase gene.

Rationale: The study did not assess integrase mutations; no INSTI-resistance mutations are reported.

Answer: NA
"""

"""
Question: 5103 

Evidence: Four drug resistance mutations in RT region were all nonnucleoside reverse transcriptase inhibitors with one E138A, one V179D, and two V179Es. Mutations in PR region were M46I and Q58E.

Rationale: No nucleoside RT inhibitor (NRTI) mutations associated with TDF resistance (e.g., K65R) were reported.

Answer: 0
"""

"""
Question: 5104 

Evidence: Sequencing covered PR and the first 300 amino acids of RT; integrase was not sequenced. No integrase inhibitor resistance mutations are described.

Rationale: INSTI-resistance mutations were not assessed or reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: Mutation sites and genotypes of drug resistance were determined using the Stanford University HIV Drug Resistance Database. We performed genotyping and drug resistance detection of AHI strains.

Rationale: The study performed genotypic resistance interpretation; no phenotypic susceptibility testing method was used.

Answer: NA
"""

"""
Question: 6102 

Evidence: Mutation sites and genotypes … were determined using the Stanford University HIV Drug Resistance Database. No phenotypic assays or IC values are described.

Rationale: The paper does not report IC50 or IC90 values.

Answer: No
"""

"""
Question: 6103 

Evidence: The study reports only genotypic mutations and their interpretation via Stanford. No phenotypic fold change data are presented.

Rationale: There are no IC50 fold change results.

Answer: No
"""

"""
Question: 6104 

Evidence: Mutation sites and genotypes … were determined using the Stanford University HIV Drug Resistance Database. No phenotypic susceptibility assay is described.

Rationale: The paper did not use a phenotypic assay.

Answer: NA
"""

"""
Question: 6105 

Evidence: The study focuses on clinical, virological (RNA, p24), and genotypic resistance characteristics. No replication capacity measurements are described.

Rationale: Replication capacity data are not reported.

Answer: No
"""

"""
Question: 6106 

Evidence: The paper reports only genotypic resistance mutations (M46I, Q58E, E138A, V179D, V179E) and their interpretation. No phenotypic drug testing is described.

Rationale: No drugs were assessed phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: HIV-1 RNA was extracted from blood … Nested PCR was performed … PCRs were sent … for direct DNA sequencing.

Rationale: Sequences were obtained from clinical samples without constructing site-directed mutants.

Answer: No
"""

"""
Question: 7102 

Evidence: A retrospective study was conducted with patients with AHI… HIV-1 RNA was extracted from blood … and sequenced. No in vitro virus passage procedures are described.

Rationale: The study did not involve laboratory passage of virus; it analyzed patient-derived sequences.

Answer: No
"""